Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

PCBIO1R Stock Latest News

Private CompaniesOscotec Refocuses Portfolio to Advance Anti-Resistance Cancer Therapy Platform3M agoBIO1R

Private CompaniesBioSpectator Inc – Weekly Recap5M agoBIO1R
Private CompaniesVetter Pharma Gains Seventh Consecutive Best Managed Company Recognition5M agoBIO1R
Private CompaniesVetter Pharma Recognition Highlights Standards in Global CDMO Market5M agoBIO1R
Private CompaniesMASH Phase 2 Data for Dual GLP-1/GCG Agonists Draw Investor Attention5M agoBIO1R

D&D Pharmatech’s DD01 Shows Statistically Significant Phase 2 MASH Efficacy

Private CompaniesD&D Pharmatech’s DD01 Shows Statistically Significant Phase 2 MASH Efficacy5M agoBIO1R

Private CompaniesBioSpectator Inc – Weekly Recap5M agoBIO1R

Private CompaniesSK Biopharm Prepares IND for First Targeted Protein Degrader Program5M agoBIO1R

Private CompaniesLotte Biologics Expands CDMO Capabilities Into ADC Hydrophilic Linker Platform5M agoBIO1R
Private CompaniesSK Biopharm Plans IND for First p300 Degrader Oncology Program5M agoBIO1R
Private CompaniesLotte Biologics Expands Into ADC CDMO With New Hydrophilic Linker Platform5M agoBIO1R
Private CompaniesBioSpectator Inc Highlights Optioned EGFR Degrader and Expanding Oncology Pipeline in Weekly Roundup6M agoBIO1R

AstraZeneca Exercises Option on Pinetree’s EGFR Degrader PTX-299 With Milestone Potential

Private CompaniesAstraZeneca Exercises Option on Pinetree’s EGFR Degrader PTX-299 With Milestone Potential6M agoBIO1R

Private CompaniesAstraZeneca Exercises Option on Pinetree’s EGFR Degrader PTX-299 With Milestone Potential Over $500 Million6M agoBIO1R

Private CompaniesCompass Therapeutics’ Tovecimig Trial Data Add PFS Strength But Raise OS Questions6M agoBIO1R

Private CompaniesCompass Therapeutics Faces Mixed Survival Data for Tovecimig in Biliary Tract Cancer Trial6M agoBIO1R
Private CompaniesHanmi Explores Oral EP300 Degrader Strategy for Solid Tumors6M agoBIO1R
Private CompaniesReCerise Advances First-in-Class TM4SF5 Antibody Toward Clinical Stage6M agoBIO1R
Private CompaniesHanmi Explores Oral EP300 Degrader Strategy for Solid Tumors6M agoBIO1R

ReCerise Therapeutics Advances TM4SF5 Antibody Toward Early Clinical Development

Private CompaniesReCerise Therapeutics Advances TM4SF5 Antibody Toward Early Clinical Development6M agoBIO1R

Private CompaniesBioSpectator Inc – Weekly Recap6M agoBIO1R

Private CompaniesY-Biologics Advances Cis-Acting Trispecific IL-2 Antibody Program Toward Planned IND Filings6M agoBIO1R